Background The aim of this study was to evaluate the feasibility of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Between 2010 and 2013, 30 patients with Stage IV HNSCC were treated in Hokkaido University Hospital with three cycles of induction chemotherapy (docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 , day 1; and 5-fluorouracil 750 mg/m 2 /day 120 h continuous infusion, every 3 weeks) followed by concurrent weekly cisplatin (40 mg/ m 2 , on weeks 1, 2, 3, 5, 6 and 7) chemoradiotherapy. Results Three courses of induction chemotherapy were performed in 25 patients (83 %) with grade 3-4 toxicities during induction chemotherapy observed in 22 patients (73 %). The major toxicities were hematologic, with 22 cases (73 %) showing grade 3-4 neutropenia. Radiotherapy was completed (70 Gy) in 29 patients (97 %), while a total of 19 patients (63 %) completed five (13 patients) or six (6 patients) courses of chemotherapy. During concurrent chemoradiotherapy, no grade 4 hematological toxicities were observed. Grade 4 dermatitis was observed in one patient, and grade 3 mucositis was observed in 12 patients. There were no treatment-related deaths during the induction chemotherapy or concurrent chemoradiotherapy. The 1-and 2-year progression-free survival rates and the 1-and 2-year overall survival rates were 86 %, 72 %, and 89 %, 81 %, respectively. Conclusion Sequential therapy composed of induction chemotherapy followed by concurrent weekly cisplatin chemoradiotherapy is feasible, showing encouraging results in patients with locally advanced HNSCC. Concurrent weekly cisplatin chemoradiotherapy following induction chemotherapy appears to be a suitable alternative to three-weekly high-dose cisplatin therapy.
Introduction
For the treatment of patients with locally advanced head and neck squamous cell carcinoma (HNSCC), concurrent chemoradiotherapy (CRT) has been demonstrated to benefit survival in many clinical trials and the meta-analysis of chemotherapy in head and neck cancer (MAHC-NC) [1] . Concurrent CRT is applied to both patients with unresectable disease and patients with resectable disease who refuse radical surgery. Three-weekly cisplatin at a dose of 100 mg/m 2 is considered to be the standard treatment for patients with advanced HNSCC [2, 3] . However, this protocol has been reported to be associated with severe acute and late toxicities. Alternative cisplatin dosing schedules are sometimes used due to improved patient tolerance [4] [5] [6] . We previously reported that weekly cisplatin at a dose of 40 mg/m 2 was easier to manage than three-weekly cisplatin [7] . Although concurrent CRT reduces the rates of locoregional failure, distant metastases represent a major cause of treatment failure in patients treated by concurrent CRT [8] .
Induction chemotherapy has been added to CRT in an attempt to decrease the likelihood of distant metastasis, improve local regional control, and aid organ preservation [9] . Two Phase III trials that focused on the efficacy of induction chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) have shown promising results [8, 10] . Cisplatin, carboplatin, docetaxel, cisplatin plus 5-FU, and cetuximab regimens have been reportedly used in concurrent CRT following induction chemotherapy [8, 9, 11, 12] . In our study, sequential therapy, consisting of induction chemotherapy involving three cycles of docetaxel and cisplatin plus 5-FU, followed by concurrent CRT with six cycles of weekly cisplatin and radiotherapy (RT) was administered.
The objectives of this study were to evaluate the compliance, response rate and toxicities of the sequential therapy for patients with locally advanced HNSCC.
Patients and methods

Patients
We retrospectively identified 30 consecutive patients with previously untreated stage IV, M0 unresectable HNSCC of the oropharynx, hypopharynx, or larynx treated with curative intent at Hokkaido University by a regimen of induction chemotherapy followed by concurrent CRT between 2010 and 2012. The criteria for inoperability were technical unresectability, low surgical curability, and organ preservation. All patients were B70 years and had not received any previous treatment for the tumor. Patients were required to be free of other active cancers as well as distant metastases. An Eastern Cooperable Oncology Group performance status of 0-1 was required in addition to the following criteria-a white cell count of at least 4,000/mm 3 , a platelet count of at least 100,000/mm 3 , a hemoglobin concentration of at least 9.5 g/dL, serum glutamic oxaloacetic transaminase and serum glutamic pyruvic transaminase levels of less than twice the upper limit of the normal range, a total bilirubin concentration of \2.0 mg/dL, a serum creatinine concentration of \1.5 g/ dL, a blood urea nitrogen concentration of\25 mg/dL, and a creatinine clearance of [60 mL/min. The disease had to be measurable or amenable to evaluation, and had to be documented as precisely as possible before treatment by endoscopy, including computed tomography (CT) and/or magnetic resonance imaging. All patients were initially evaluated by a multidisciplinary team consisting of head and neck surgeons, radiation oncologists, and medical oncologists. The tumors were classified according to the 2002 Union Internationale Contre le Cancer (UICC) staging system.
HPV typing by multiplex PCR
The HPV infection status for patients with oropharyngeal squamous cell carcinoma (OPSCC) was analyzed using multiplex PCR, which can detect 16 HPV genotypes (types 6, 11, 16, 18, 30, 31, 33, 35, 39, 45 , 51, 52, 56, 58, 59, and 66), as described previously [13] .
Induction chemotherapy
Induction chemotherapy consisted of docetaxel at 75 mg/ m 2 on day 1, cisplatin at 75 mg/m 2 on day 1, and 5-FU at a dose of 750 mg/m 2 by 24-h continuous infusion for 5 days; three cycles at 3-week intervals were planned. All patients were given adequate hydration and anti-emetics (5-HT3 antagonists and dexamethasone and/or neurokinin-1 receptor antagonist).
Concurrent chemotherapy
After induction chemotherapy, concurrent CRT was initiated between 3 and 4 weeks after the last chemotherapy cycle. Weekly cisplatin was administered at a dose of 40 mg/m 2 on weeks 1, 2, 3, 5, 6 and 7 of RT. Patients received prophylactic hydration and 5-HT3 antagonists plus dexamethasone and/or neurokinin-1 receptor antagonist for anti-emetic prophylaxis. The intended maximum total dose of cisplatin was 240 mg/m 2 . Preparation for percutaneous endoscopic gastrostomy feeding prior to treatment was recommended. The use of non-steroidal antiinflammatory drugs was avoided in order to prevent any synergistic toxic effects with cisplatin on renal function.
Radiotherapy
A standard dose of 70 Gy was delivered in 35 daily fractions over 7 weeks to all of the patients. All of the patients received RT (40 Gy/20 fractions/4 weeks) in the form of 4 or 6 MV photons, produced by a linear accelerator to the primary sites and regional lymphatic area. The treatment was planned using a CT simulator and a three-dimensional dose-calculation computer. For patients who were suspected of having lymph node metastases, the lower neck region and supraclavicular fossa were prophylactically irradiated with a total of 40 Gy using an anterior single port. Electron beams were used to boost the dose delivered to the posterior cervical lymph nodes. The dose delivered to the spinal cord was kept \40 Gy in all instances. After the initial dose of 40 Gy had been administered, an additional dose of 30 Gy was given with a shrunken field in 15 fractions over 3 weeks.
Evaluation of toxicity and response
Toxicities were graded using the Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 3.0. For measurable lesions, responses were evaluated from CT scans of the neck and chest 2 weeks after the last course of induction chemotherapy and 6-8 weeks after RT using the Response Evaluation Criteria in Solid Tumors (RECIST).
Statistical considerations
Data on disease site, tumor-node-metastasis (TNM) stage, RT dose/fractionation and chemotherapy regimen were collected. Incidences of delays to therapy, acute toxicity, dose reduction and missed treatments for both chemotherapy and RT were also recorded.
The primary endpoint was treatment compliance. Complete treatment delivery was defined as the administration of the 70 Gy RT dose within 63 days, and the completion of five or six courses of cisplatin. Treatment compliance was evaluated based on the rate of complete treatment delivery.
Cases of persistent or recurrent primary disease after the completion of CRT were considered to be local failures, even if salvage was successful. The probabilities of overall survival, which included death from any cause, and the local control rates (the local progression-free rates computed from the beginning of treatment until the time of local relapse) were calculated by the Kaplan-Meier method.
Results
Patient characteristics
Of the 61 HNSCC patients who fulfilled the eligibility criteria described in the 'Patients and methods' section, 30 (27 males, 3 females) were enrolled in the study. Table 1 shows the patient and tumor characteristics. The patients ranged in age from 40-69 years (median 57 years). The most common site of the primary disease was the oropharynx (15 patients), followed by the hypopharynx (13 patients) and larynx (2 patients). The clinical stages are listed in Table 2 . The number of patients with Stage IVA and IVB disease was 24 and 6, respectively. The median follow-up period was 18 months (range 5-38 months).
Of the 15 patients with OPSCC, HPV infection status was analyzed in 11. Six patients were found to be HPV positive, with five positive for HPV16, and one positive for HPV18 (Table 3) .
Induction chemotherapy
Of the 30 patients, 25 (83 %) underwent three cycles of treatment at the planned doses. Three patients (10 %) received two cycles, and 2 patients (7 %) received only one cycle due to toxicity (Tables 3, 4 ). The median day of administration of the second cycle of induction chemotherapy was day 23 (range 21-30), and the median day of administration of the third cycle of induction chemotherapy was day 44 (range 42-58). No dose modifications were made in any patient.
The toxicity of the induction chemotherapy is summarized in Table 5 . Grade 3-4 toxicities during induction chemotherapy were recorded in 22 patients (73 %). The major toxicities were hematologic, with 22 cases (73 %) of grade 3-4 neutropenia. Grade 3 diarrhea was observed in 3 patients (10 %). The overall response rate after induction chemotherapy was 83 % (25/30) (Tables 3, 4) . Only one patient experienced tumor progression, due to the appearance of contralateral neck node metastasis, and bilateral neck dissection was required before concurrent CRT (Case no. Table 4 ). Another patient with stable disease with regard to lymph nodes after induction chemotherapy underwent neck dissection followed by chemoradiation as the neck disease was considered to be incurable by chemoradiation (Case no. 7, Table 3 ). (Tables 3, 4 ). Acute toxicities during the concurrent chemoradiation are summarized in Table 6 . No grade 4 hematological toxicities were observed. Grade 4 dermatitis was observed in one patient, and grade 3 mucositis was observed in 12 patients. There were no treatment-related deaths during the induction chemotherapy or concurrent CRT.
16,
Response after completion of concurrent CRT (Tables 3, 4) After completion of concurrent CRT, 26 patients (87 %) achieved a complete response, and only 1 (3 %) experienced disease progression due to lung metastasis (Case no. 16, Table 4 ). Two patients who achieved a partial response or stable disease for the neck site with complete response for the primary site later underwent salvage neck dissection for residual disease after chemoradiation (Case no. 5, Table 3 and Case no. 26, Table 4 ).
Outcomes
Progression-free survival and overall survival are shown in Fig. 1 . The 1-and 2-year progression-free survival rates and the 1-and 2-year overall survival rates were 86 %, 72 %, and 89 %, 81 %, respectively. The 1-and 2-year progression-free survival rates as well as the 1-and 2-year overall survival rates were all 83.3 %.
Of the patients with HPV-positive OPSCC, the 1-and 2-year progression-free survival rates and the overall survival rates were both 83.3 %. Of the patients with HPVnegative OPSCC, the 1-and 2-year progression-free survival rates and the 1-and 2-year overall survival rates were 100 %, 60 %, and 100 %, 80 %, respectively. There were no statistical differences in survival rates between the HPV-positive and HPV-negative patients.
Discussion
This study shows that induction DCF chemotherapy followed by concurrent weekly cisplatin CRT was feasible for the treatment of and well-tolerated by patients with locally advanced HNSCC.
Eighty percent of patients in this study completed three courses of induction DCF chemotherapy with acceptable toxicity. The most common grade 3-4 toxicity was neutropenia (73 %), with 27 % experiencing febrile neutropenia during induction chemotherapy. In other studies on the use of DCF induction chemotherapy, the rate of grade 3-4 neutropenia was reported to vary from 31.5-83 % [8, 10, [14] [15] [16] , and the rate of febrile neutropenia was reported to be 5.2-18 % [8, 10, [14] [15] [16] . Even though our results are at the higher end of the previously reported rates, there were no treatment-related deaths during DCF induction chemotherapy. The overall response rate of the induction chemotherapy was 83 %. This response rate was similar to those of other studies on DCF induction chemotherapy. In our study, weekly cisplatin concurrent CRT was administered after induction chemotherapy. Sixty-three percent of patients received [200 mg/m 2 of cisplatin after induction chemotherapy. We previously reported that 59 % of patients received [200 mg/m 2 of cisplatin when undergoing concurrent weekly cisplatin CRT [7] . These results suggest that the use of DCF induction chemotherapy does not prevent the use of concurrent weekly cisplatin chemotherapy.
The treatment of several series of patients with a combination of DCF induction chemotherapy and cisplatinbased concurrent CRT has been reported. In the TREM-PLIN study [12] , concurrent cisplatin 100 mg/m 2 /3 week was administered. Forty-two percent of the patients received three courses of cisplatin, 42 % received two cycles, and 13 % received one cycle. Prestwich et al. [17] reported that concurrent cisplatin 100 mg/m 2 /3 week was administered after DCF induction chemotherapy. Five percent of the patients received three courses of cisplatin, 61 % received two cycles, and 29 % received one cycle. They concluded that compliance over the three courses of concurrent chemotherapy was poor. Weekly cisplatin might be more easily managed than three-weekly cisplatin as patients can be monitored for toxicity more regularly, and the schedule can be changed, based on the patient's condition, before the effects become severe.
There were no treatment-related deaths during the concurrent weekly cisplatin CRT, and the toxicities of the concurrent weekly cisplatin CRT were considered acceptable. No patients were observed with grade 3 or greater renal dysfunction. Pain control was achieved using opioids in place of NSAIDs to avoid renal dysfunction and this may have attenuated the potential for severe renal dysfunction. Based on a multicenter phase II study, Zenda et al. [18] reported that an opioid-based systemic control program during chemoradiation may be helpful in improving compliance with chemoradiation. Grade 3 mucositis was observed in 40 % of patients during the concurrent weekly cisplatin CRT. Many of the patients were provided with gastrostomies before radiation, and several reports have shown that gastrostomies also improved compliance of CRT [18] [19] [20] . These supportive procedures are necessary for successful concurrent cisplatin-based CRT.
The complete response rate after treatment was 86 % in this study. In other studies using sequential therapy, i.e., DCF induction chemotherapy followed by concurrent CRT, the complete response rate was reported to be 50 % by Paccagnella et al. [11] and 86 % by Prestwich et al. [17] . Sequential therapy, therefore, appears to result in high response rates in locally advanced HNSCC.
In this study, 50 % of the patients had oropharyngeal cancer, which is similar to the rates of oropharyngeal cancer patients in other studies. HPV-positive oropharyngeal cancer has been shown to respond better to chemotherapy and RT in comparison with HPV-negative oropharyngeal cancer. We have previously reported that Japanese patients with HPV-positive OPSSC have markedly superior survival rates compared to those with HPVnegative OPSCC [13] . However, there were no differences in survival rates between HPV-positive and HPV-negative patients in this study. We speculate that this was due to the small patient population and short follow-up period. RTOG 1016 is now underway to determine whether treatment can be de-intensified for HPV-positive OPSCC. However, several patients with HPV-positive OPSCC are known to develop distant metastasis. Spector et al. [21] reported that the OPSCC patients with matted nodes have a risk of distant metastasis. Although the value of induction chemotherapy prior to definitive concurrent CRT has not been firmly established, this sequential therapy should be considered for selected patients with locally advanced disease, including those with HPV-positive OPSCC.
In conclusion, induction docetaxel, cisplatin, and 5-FU chemotherapy combined with weekly cisplatin concurrent CRT is a feasible treatment for and has high rates of complete response in locally advanced HNSCC patients. While the role of sequential therapy remains inconclusive, this sequential therapy should be considered for patients with locally advanced HNSCC.
